OT mobile menu

Search form


Lung Cancer Targets

Study Identifies How Lung Tumors Acquire Immunotherapy Resistance

NSCLC can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells. Image © Tashatuvango/ Shutterstock.com

Image © koya979 / Shutterstock.com

Lung Cancer Targets

A new study has found that high tumor mutation load is associated with older age, absence of oncogenic mutations, and presence of tumor suppressor gene mutations.

Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.

The FDA has approval pembrolizumab (Keytruda), in combination with chemotherapy, for the first-line treatment of patients with metastatic non-squamous non–small-cell lung cancer.

Researchers report that an analysis of ALK copy number in circulating tumor cells before starting crizotinib treatment and after 2 months of crizotinib treatment may provide a biomarker for predicting the effectiveness of the drug.

Peripheral blood analysis may provide valuable insights into non-small cell lung cancer patients’ responses to programmed cell death 1 (PD-1)-targeted therapies.

Circulating tumor DNA blood tests can rapidly identify treatment-targetable tumor mutations in patients diagnosed with non–small-cell lung cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.


Subscribe to Lung Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.